Dilated cardiomyopathy (DCM) is the second most common cause of heart disease in dogs, and medical management of the secondary signs is the only therapeutic option. The outcome for affected dogs depends on the stage of disease and the breed. Once diagnosed, dogs typically exhibit rapid and uniform progression to congestive heart failure (CHF), with most living less than 6 months.
To date, 23 dogs have been screened for enrollment in this study, ten dogs have undergone treatment (enrolled), three have died after enrollment in the study but prior to treatment and ten dogs have had vector antibody titers too high to safely treat. One dog is scheduled to be treated the third week of March. We continue to advertise the clinical trial by various methods in order to meet our goal of treating 12 dogs.
End-Year-8 Research Update Dr. Sleeper gene therapy for DCM.
